

SOME RECENT PATENT APPLICATIONS IN THE AREA OF RECEPTOR SCREENING

Patent #	Subject	Assignee	Author	Status*
WO 9621726	New retinoid-inducible response element. Used to develop products for the treatment of diseases in which retinoid X receptor-mediated processes are involved.	Salk Inst, La Jolla, CA; Univ Texas Austin, TX	Evans RM,; Mangelsdorf DJ, Willy P J	7/18/96 A1
WO 9621728	Transgenic animals with defective thyroid receptor gene, TR α 1 gene. Useful for screening compounds having agonist or antagonist activities.	Karo Bio AB Huddinge, Sweden	Vennstrom B	7/18/96 A2
US 5532132	Determination of effect of compounds on cytoskeletal stiffness as measure of effect on complex of plasminogen activator and its receptor and inhibitor.	Univ Harvard, Cambridge, MA; Univ Paris, France	Barlovatz-Meimon G, Fredberg JJ, Wang N	7/2/96 A
WO 95US16261	New corticotropin-releasing factor antagonist peptide(s). Used to treat disorders involving the endocrine system, the central nervous system, and the gastrointestinal tract.	Salk Inst, La Jolla, CA	Rivier JEF	6/27/96 A2
WO 9619238	Inhibition of tumor growth by depleting the intracellular iron levels of tumor cells using iron chelator and monoclonal IgG anti-transferrin receptor antibody.	Univ Iowa Res Found, Iowa City, IA	Kemp JD	6/27/96 A1
EP 718308	New sulfur-containing branched peptide derivatives. Used for inhibiting incorporation of modified low density lipoprotein into macrophage(s) (e.g., for treatment of arteriosclerosis).	Protein Eng Res Inst, Tanpaku Kogaku	Doi T, Imanishi T, Kodama T, Nakamura H, Tanaka T, Kenkyusho KK	6/26/96 A2
WO 9618649	New cyclic corticotropin-releasing factor agonist peptide(s). Used to stimulate the function of the pituitary-adrenal-cortical axis and for modulating blood flow.	Salk Inst, La Jolla, CA	Rivier J E F	6/20/96 A1
WO 9618650	New receptor obtained from rat forebrain tissue. Used to develop products for treating disorders such as anxiety, mania, depression, epilepsy, or Parkinson's disease.	SmithKline Beecham King of Prussia, PA	Chan WN, Herdon HJ, Jerman JC	6/20/96 A1
JP 8154682	G-protein conjugate receptor protein. Useful in ligand determination, antibody production, drug screening, and design and receptor binding assay system development.	Takeda Chem Ind Ltd, Osaka		6/18/96 A
JP 8143597	DNA encoding human neurotensin receptor protein. Useful for screening for (ant)agonists used to treat Parkinson's disease, depression, dementia, retrograde esophagitis, etc.	Takeda Chem Ind Ltd, Osaka		6/4/96 A
WO 9606188	Synthetic random nucleotide sequences encoding ligand binding domains. Identified by screening library of vectors or peptide(s) and useful for gene therapy and diagnosis.	Cytogen Corp, Princeton, NJ	Fowlkes DM, Rodwell JD	2/29/96 A1
WO 9530026	Transcription factor-DNA binding assay. Used to identify agents modulating gene transcription.	Tularik Inc, San Francisco, CA	Baichwal VR, Peterson MG, Strulovici B	11/9/95 A1
WO 9505600	Screening for central nervous system disorders caused by autoimmune disease using antiglutamate receptor auto-antibodies as indicators of the disorder.	Salk Inst, La Jolla, CA; Duke Univ, Durham, NC	Heinemann SF, Mcnamara JO, Rogers SW	2/23/95 A1
AU 9466122	New fusion protein of bulky hydrophilic peptide and hydrophobic component containing specific cleavage site. Useful for production and purification of hydrophobic peptide(s), especially new monomeric β -amyloid peptide.	Hoffmann-La Roche, Basel, Switzerland	Draeger N, Jakob P, Doebeli H, Stueber D, Trottman GH, Huber T	1/27/95 A
WO 9216222	Compositions comprising calcitonin and insulin or glucagon. Useful as a hypo- or hyperglycemic agent for treating type I and II diabetes mellitus and other insulin-requiring conditions.	Amylin Pharm Inc, San Diego, CA	Beaumont K, Rink TJ, Young AA	10/1/92 A1

Source: Derwent World Patents Index, 1996. *Key: (WO) A, open for public inspection (OPI) application; A1, OPI application with international search report (from 9220); A2, OPI application without international search report (from 9220); (US) A, examined granted patent; (JP) A, OPI application published before examination (Kokai Tokyo Koho); (AU) A, OPI application without examination; (EP) A2, OPI application - examiner's search report not included (from 9221).